Early Intervention in Cystic Fibrosis Exacerbation (eICE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University CF Clinic
-
-
Washington
-
Seattle, Washington, United States, 98104-2499
- University of Washington
-
Seattle, Washington, United States, 98105-5371
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CF diagnosis confirmed with sweat test, abnormal nasal potential difference and/or genetic testing
- Age 14 and older
- Able to perform spirometry
- Clinically stable without antibiotic treatment for a pulmonary exacerbation in the two weeks prior to the screening visit
- Forced expiratory volume in the first second (FEV1) greater than 25% of predicted at screening
Exclusion Criteria:
- History of solid organ transplant
- Participation in any interventional trial within the last 30 days
- Inability to speak and read the English language well enough to complete questionnaires
- Colonization with Burkholderia cepacia genomovar III within the last 24 months
- Currently receiving antimicrobial treatment specifically used to treat active non-tuberculosis mycobacterium
- Confirmed diagnosis of allergic bronchopulmonary aspergillosis (ABPA) as defined by the Cystic Fibrosis Foundation (CFF) guidance document that is being actively treated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Standard Care
Subjects will receive education about signs and symptoms indicative of worsening CF.
|
|
|
Active Comparator: Home monitoring
Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
|
subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in FEV1
Time Frame: 12 months
|
The primary outcome variable is FEV1 which will be obtained at quarterly study visits.
The primary analysis will use a linear mixed effects model incorporating all FEV1 measurements to estimate the 52-week change in FEV1
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cystic Fibrosis Respiratory Symptom Diary (CFRSD)
Time Frame: 12 months
|
Change in CF respiratory symptoms as measured by the CFRSD.
The CFRSD consists of 8 items which quantify symptom severity for the previous 24 hours to capture the magnitude of symptoms in stable CF, during medically treated CF exacerbations, and during recovery from an exacerbation.
The CFRSD also includes emotional and activity impacts.
Emotional impacts include frustration, sadness/depression, irritability, worry, and difficulty sleeping.
Activity impacts include time spent sitting or lying down, reduction of usual activities, and missing school or work.
will be analyzed using a linear mixed effects model incorporating baseline randomization factors FEV1 (<50%, 50-75%, and >75% predicted) and age (14-18 & 19+), treatment group, time (in weeks) and the interaction between treatment and time.
The range of scores is 8 to 40 with higher scores indicating more severe symptoms.
|
12 months
|
|
Pulmonary Exacerbations
Time Frame: 12 months
|
Percentage of participants who experienced at least one acute pulmonary exacerbation
|
12 months
|
|
Change in Health Related Quality of Life Scores as Assessed by the Cystic Fibrosis Questionnaire Revised (CFQ-R) (Respiratory Subscale Only(
Time Frame: Change from baseline to 12 months
|
Change in health related quality of life as measured by the Cystic Fibrosis Questionnaire revised (CFQ-R)will be analyzed using a linear mixed effects model incorporating baseline randomization factors FEV1 (<50%, 50-75%, and >75% predicted) and age (14-18 & 19+), treatment group, time (in weeks) and the interaction between treatment and time.
The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning, and Social Functioning.
Only the respiratory subscale of the the CFQ-R was evaluated.
This ranges from 0 to 100 with higher scores indicating better respiratory quality of life.
A negative number indicates a decrease in respiratory quality of life.
|
Change from baseline to 12 months
|
|
Treatment Burden
Time Frame: Change from baseline to 12 months
|
Change in treatment burden as measured by the Cystic Fibrosis Questionnaire revised (CFQ-R)will be analyzed using a linear mixed effects model incorporating baseline randomization factors FEV1 (<50%, 50-75%, and >75% predicted) and age (14-18 & 19+), treatment group, time (in weeks) and the interaction between treatment and time.
Scores range from 0-100 with higher scores indicating less treatment burden.
|
Change from baseline to 12 months
|
|
Change in Prevalence of Resistant Species of Bacteria
Time Frame: 12 months
|
Change in prevalence of resistant species of bacteria (Methicillin Resistant S. aureus, Pseudomonas aeruginosa, Burkolderia cepacia, Stenotrophomona maltophilia, Achromobacterxylosoxidans) in sputum between baseline and final visit (Visit 5 or early withdrawal) will be summarized by treatment group.
|
12 months
|
|
Serious Adverse Events (SAE)
Time Frame: 12 months
|
Adverse event rates will be coded by body system and MedDRA classification term.
Adverse events will be tabulated by treatment group and will include the number of subjects for whom the event occurred, the rate of occurrence, and the severity and relationship to study participation or study procedures.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Noah Lechtzin, MD, Johns Hopkins University
- Principal Investigator: Christopher Goss, MD, University of Washington
Publications and helpful links
General Publications
- VanDevanter EJ, Heltshe SL, Skalland M, Lechtzin N, Nichols D, Goss CH. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis. J Cyst Fibros. 2021 Nov;20(6):932-936. doi: 10.1016/j.jcf.2021.02.012. Epub 2021 Mar 5.
- Lechtzin N, Mayer-Hamblett N, West NE, Allgood S, Wilhelm E, Khan U, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, Gibson RL, Orenstein D, Milla C, Clancy JP, Antony V, Goss CH; eICE Study Team. Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1144-1151. doi: 10.1164/rccm.201610-2172OC.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL001
- LECHTZ10A0 (Other Grant/Funding Number: Cystic Fibrosis Foundation)
- R01HL103965 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.